Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Open access
3,961
Views
3
CrossRef citations to date
0
Altmetric
Genetic Disease
Limitations of standard cost-effectiveness methods for health technology assessment of treatments for rare, chronic diseases: a case study of treatment for cystic fibrosis
Jaime L. Rubina Vertex Pharmaceuticals Incorporated, Boston, MA, USACorrespondence[email protected]
, Andrea Lopeza Vertex Pharmaceuticals Incorporated, Boston, MA, USA
, Jason Bootha Vertex Pharmaceuticals Incorporated, Boston, MA, USA
, Penilla Guntherb Former Member of Swedish Parliament, Stockholm, Sweden
& Anupam B. Jenac Harvard Medical School, Boston, MA, USA
Pages 783-791
|
Received 29 Mar 2022, Accepted 11 May 2022, Published online: 09 Jun 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.